|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0017262,
umls-concept:C0036525,
umls-concept:C0086418,
umls-concept:C0185117,
umls-concept:C0205225,
umls-concept:C0205245,
umls-concept:C0376358,
umls-concept:C0699749,
umls-concept:C0699794,
umls-concept:C0851285,
umls-concept:C1336645,
umls-concept:C1367028,
umls-concept:C1412836,
umls-concept:C1420805,
umls-concept:C1522484,
umls-concept:C1710303,
umls-concept:C2745888,
umls-concept:C2911684
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2006-8-14
|
|
pubmed:abstractText |
Late-stage prostate cancer patients are refractory to hormone therapy and exhibit a high propensity to develop skeletal metastasis. In this regard, the role of a novel cytokine system belonging to the tumor necrosis factor (TNF) family that is critical for osteoclastic osteolysis and that consists of receptor activator of NF-kappaB ligand (RANKL), its receptor (RANK), and decoy receptor osteoprotegerin (OPG) is of potential interest.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Carrier Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Glycoproteins,
http://linkedlifedata.com/resource/pubmed/chemical/Membrane Glycoproteins,
http://linkedlifedata.com/resource/pubmed/chemical/Osteoprotegerin,
http://linkedlifedata.com/resource/pubmed/chemical/Prostate-Specific Antigen,
http://linkedlifedata.com/resource/pubmed/chemical/RANK Ligand,
http://linkedlifedata.com/resource/pubmed/chemical/Receptor Activator of Nuclear...,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Cytoplasmic and Nuclear,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Tumor Necrosis Factor,
http://linkedlifedata.com/resource/pubmed/chemical/TNFRSF11A protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/TNFRSF11B protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/TNFSF11 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Markers, Biological
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
0008-543X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
107
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
289-98
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:16752412-Aged,
pubmed-meshheading:16752412-Carcinoma,
pubmed-meshheading:16752412-Carrier Proteins,
pubmed-meshheading:16752412-Glycoproteins,
pubmed-meshheading:16752412-Humans,
pubmed-meshheading:16752412-Male,
pubmed-meshheading:16752412-Membrane Glycoproteins,
pubmed-meshheading:16752412-Middle Aged,
pubmed-meshheading:16752412-Neoplasm Metastasis,
pubmed-meshheading:16752412-Neoplasm Staging,
pubmed-meshheading:16752412-Osteoprotegerin,
pubmed-meshheading:16752412-Prognosis,
pubmed-meshheading:16752412-Prostate-Specific Antigen,
pubmed-meshheading:16752412-Prostatic Neoplasms,
pubmed-meshheading:16752412-RANK Ligand,
pubmed-meshheading:16752412-Receptor Activator of Nuclear Factor-kappa B,
pubmed-meshheading:16752412-Receptors, Cytoplasmic and Nuclear,
pubmed-meshheading:16752412-Receptors, Tumor Necrosis Factor,
pubmed-meshheading:16752412-Tumor Cells, Cultured,
pubmed-meshheading:16752412-Tumor Markers, Biological,
pubmed-meshheading:16752412-Up-Regulation
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation.
|
|
pubmed:affiliation |
Department of Medicine, McGill University Health Centre, Montreal, Quebec, Canada.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
